Symbols

NUWE

Nuwellis·NASDAQ

--(--)

NUWE fundamentals

NUWE Q4 2025 Earnings

Nuwellis (NUWE) released its earnings on Mar 10, 2026: revenue was 2.42M (YoY +4.39%), beat estimates; EPS was -1.5 (YoY +91.88%), beat estimates.

Revenue / YoY

2.42M

+4.39%

EPS / YoY

-1.5

+91.88%

Report date

Mar 10, 2026

NUWE Earnings Call Summary for Q4,2025

Strategic Restructuring Success: 2025 transition to cardiorenal focus and operational streamlining drove Q4 revenue growth (+4% YoY) and gross margin expansion to 68.2%.
Pediatric Growth Catalyst: NIH grant and 14% YoY growth in pediatric segment validate long-term clinical value.
Rendiatech Integration: Mid-2026 launch of enhanced ICU fluid management technology to drive utilization in existing accounts.
Financial Strength: $1.2M cash on hand, no debt, and disciplined expense management reducing operating expenses by $0.4M YoY.

Earnings

EPS

Revenue

Revenue & Expenses

NUWE has released its 2025 Q4 earnings report, with revenue of 2.42M, reflecting a YoY change of 4.39%, and net profit of -2.42M, showing a YoY change of -64.99%. The Sankey diagram below clearly presents NUWE's revenue sources and cost distribution.

Key Indicators

Nuwellis (NUWE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Nuwellis (NUWE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Nuwellis (NUWE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Nuwellis (NUWE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown